Good day, ladies and gentlemen. Thank you for standing by. Welcome to today's conference call to discuss LifeVantage's third quarter fiscal 2022 results. At this time, all participants are in a listen-only mode. Following the formal remarks, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up. Hosting today's conference will be Reed Anderson with ICR. As a reminder, today's conference is being recorded. Now, I would like to turn the conference over to Mr. Anderson. Please go ahead, sir. Thank you. Good afternoon, and welcome to LifeVantage Corporation's conference call to discuss results for the third quarter of fiscal 2022. On the call today from LifeVantage with prepared remarks are Steve Fife, Chief Executive Officer, and Carl Aure, Chief Financial Officer. By now, everyone should have access to the earnings release, which went out this afternoon at approximately 4:05 P.M. Eastern Time. If you have not received the release, it is available on the investor relations portion of LifeVantage's website at www.lifevantage.com. This call is being webcast and a replay will be available on the company's website as well. Before we begin, we would like to remind everyone that our prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. These statements do not guarantee future performance, and therefore undue reliance should not be placed upon them. These statements are based on current expectations of the company's management and involve inherent risks and uncertainties, including those identified in the Risk Factors section of LifeVantage's most recently filed Form 10-K and 10-Q. Please note that during today's call, we will discuss non-GAAP financial measures, including results on an adjusted basis. Management believes these financial measures can facilitate a more complete analysis and greater transparency into LifeVantage's ongoing results of operations, particularly when comparing underlying operating results from period to period. We've included a reconciliation of these non-GAAP financial measures with today's release. This call also contains time-sensitive information that is accurate only as of the date of this live broadcast, May third, two thousand and twenty-two. LifeVantage assumes no obligation to update any forward-looking projection that may be made in today's release or call. Now I will turn the call over to Steve Fife, the Chief Executive Officer of LifeVantage. Thanks, Reed, and good afternoon, everyone. Thank you for joining us today. With me is Carl Aure, our Chief Financial Officer, who will join me with prepared remarks before we turn the call over for Q&A. During the third quarter, the operating environment remained challenging, but we continued to take steps to strengthen our business and drive long-term value for shareholders. Our financial position remains strong with almost $18 million of cash, and we are proud to announce the company's first quarterly dividend of $0.03 per common share. This action underscores our commitment to enhancing shareholder value, as well as confidence in our outlook for the future. Revenue for our third fiscal quarter were $50 million, down 3% year-over-year, as the duration of COVID restrictions continues to weigh on distributors and customer engagement. Excluding the negative impact of foreign currency fluctuation, third quarter revenue declined less than 1%. Internationally, total active accounts grew by 4.3%, and revenue increased 9.3% or 17.3% when adjusted for the negative impact of foreign currency. This was offset by declines in the Americas region. Despite the challenges, we made progress hosting some distributor events in the quarter. In February, we hosted an Elite Academy in Orlando, which was a kickoff event for many of our leadership groups. We offered both virtual and in-person attendance with strong messages confirming our commitment to being the "and" company by supporting product sales through both business opportunities and customer growth. At this Elite Academy, we announced our newest event, Activate 2022, which continues our "and" company commitment and will be held in Salt Lake City in June. The leaders left Elite Academy in Orlando excited for the future. In March, we held a Pro Five Summit and welcomed some of our newest leaders to our global headquarters. With two full days of training and inspiration, our Pro Fives left with an energized commitment to their LifeVantage businesses. The training continues with a 90-day support push, with our Pro Ten leaders providing continuous insights and content that supports our Pro Fives as they build to their next rank. In the Philippines, we continue to see consistent growth, which in turn is reengaging leaders in other markets. We saw a new Elite Pro Nine in Australia with a significant percent of growth coming from the Philippines. We're also encouraged by the first meeting of our international general managers since the pandemic to align and create a roadmap for next fiscal year. This event inspired many strong global programs and incentives that we are excited to share with our leaders at Activate 2022. The 120-day post-purchase program we mentioned last quarter produced encouraging results relative to our customer journey campaign, including a 7.8% conversion rate for non-subscribers moving to subscription, a 1.85% conversion rate for test product offers to subscribers, and a 20% improvement in attrition for distributors versus average enrollments. As we discussed last quarter, the direct selling business has been evolving to a model that is more agile, more inclusive, and creates multiple pathways to entrepreneurial success. Accordingly, our business has also been evolving and our leadership team and board are fully aligned with our approach to this new paradigm. We are focused on three primary areas to position the company for accelerated growth and significant long-term value creation. People, product, and customer experience. On our call in February, I introduced the addition of two new members of our executive team, Julie Boyster as our Chief Marketing Officer, and Rob Harris as our Chief Digital Officer. Julie, Rob, and the entire leadership team have been hard at work over the past quarter to ensure all cross-functional teams are focused and working together to enhance these three key areas. On the marketing front, Julie and her team have developed and introduced a new product strategy that establishes guardrails for future product line growth and sets a clear path for LifeVantage being known worldwide for products that activate healthy living. The strategy expands the revolutionary activation benefit found in our flagship product, Protandim Nrf2 Synergizer, and will allow us to develop future products and product lines rooted in the science of nutrigenomics. While the science behind our products remains at the forefront, other product elements, like being demonstrable and delightful to consumers, have been added to the strategy to better align with the product experiences consumers are demanding in today's world. As part of the new product strategy, additional investments are being made within the product team. The product and content teams are using a new marketing framework that ensures the consumer's wants and needs are addressed in all messaging and materials in an effort to increase consumer understanding of LifeVantage products while also increasing customer wallet share. This approach also allows for our products to be more easily shared on various digital channels, including social media. A more comprehensive social media strategy has been built to strengthen our digital presence. I'll be sharing more on this in the future quarters. The digital team is also committed to delivering on our three core areas. Rob's recent focus has been on our mobile app and implementing enhancements that improve a distributor's ability to share LifeVantage branded content with their team and customers. We also added improved reporting capabilities to help distributors track and achieve incentive goals. In coming quarters, digital efforts around shopping experience will intensify, refocusing homepage and site navigation on shopping and the discovery of LifeVantage products, as well as aligning the user experience across mobile platforms. We're also working to simplify mobile responsive subscription management online to make it easier to customize subscriptions. Consumer experience has also been enhanced through our sales organization and our ongoing distributor sales incentives. You've heard me mention our MVP incentive. This long-term incentive takes the simple approach of finding three distributors and helping them increase product sales. This latest MVP iteration has started to gain a lot of traction and saw a 37% increase after one month. We have doubled our training efforts, enhanced recognition at all levels, and are releasing several enhancements to MVP at our Activate 2022 event. Also on the incentive front, the qualification of our annual incentive trip will wrap up in June with an increased number of people within striking distance of our trip of a lifetime event in Croatia. Leaders are currently driving towards the rank of Pro Four to help ensure they get to experience this amazing trip. As we expand on the end company strategy, supporting entrepreneurs, growing businesses in a myriad of ways, we are getting clearer on the key behaviors that predict success in our field. One of those critical activities that we have focused on this year is enrolling distributors that are excited about our products. Our data shows that if we can help a new person enroll a distributor in their first 60 days, we will see greater distributor enrollments and retention into our business. To support this, beginning in May, distributor enrollment packs will contain three shareable codes that new distributors can share with their prospects and consumers. I also want to go a little deeper into our new event, Activate 2022, and how it is contributing to our pillars of people, product, and consumer experience. At this event in June, LifeVantage distributors will meet in Salt Lake City for a weekend of vision alignment, announcements, incentive enhancements, and a new product. The event will consist of three general sessions Activate Your Business, Activate Your Confidence, and Your Activation Plan, providing a new template for future gatherings with an increased focus on aligned promotions and incentives, social experiences, and training enhancements. Activate 2022 sets up fiscal year 2023 for success and is designed to lead the organization to even more exciting alignment and growth at our global convention in October. In summary, energy levels are high, and we continue to make steady progress towards transforming our organization to drive accelerating growth in the future. We have a solid foundation with a large established base of loyal customers and distributors, and our strong financial position ensures we have sufficient resources to execute our plan. Now let me turn the call over to Carl to review our third quarter financial results. Carl. Thank you, Steve. Please note that I will be discussing our non-GAAP adjusted results. You can refer to the GAAP to non-GAAP reconciliations in today's press release for additional details. Third quarter revenue was $50 million, down 3% on a year-over-year basis and 4.2% sequentially from the second quarter. Foreign currency fluctuations negatively impacted revenue by $1.2 million in the third quarter. Excluding the negative impact of foreign currency fluctuations, third quarter revenue was down $0.3 million or less than 1%. Revenue in the Americas declined 8.2% compared to the prior year period to $33.4 million, primarily driven by a 10.7% decrease in total active accounts. Revenue in our Asia Pacific and Europe region increased 9.3% to $16.6 million, driven by a 4.3% increase in total active accounts and initial revenues associated with the launch of the Philippines. We continue to be encouraged by the positive results we are seeing in Australia and New Zealand due to continued distributor leadership development and advancement as well as continued momentum in Thailand and China. This was partially offset by lower revenue in Japan, which was attributable to the negative impact of foreign currency. On a constant currency basis, revenues in Japan increased slightly by 0.1%. Gross margin was 80.7% in the third quarter compared to 82.9% in the prior year period. The decrease in gross margin was due to increased inventory obsolescence expenses, elevated shipping expenses along with shifts in geographic and product sales mix. Commissions and incentive expense in the third quarter declined $1.9 million year-over-year. As a percentage of revenue, commissions and incentive expense declined 240 basis points to 46.4% versus year-ago levels, which was driven by changes in the timing and magnitude of promotional and incentive programs. Non-GAAP adjusted SG&A expense slightly increased by $0.3 million compared to the prior-year quarter and was up 140 basis points as a percentage of revenue to 29.3%. Adjusted operating income was $2.5 million, compared with $3.2 million in the prior-year period. Adjusted net income was $1.7 million or $0.12 per fully diluted share in the third quarter, compared to adjusted net income of $2.8 million or $0.20 per fully diluted share in the comparable period last year. We recorded income tax expense of $0.6 million in the third quarter compared to tax expense of $0.1 million a year earlier. For fiscal year 2022, we expect our effective tax rate will be approximately 23%. Adjusted EBITDA for the third quarter was $3.4 million or 6.8% of revenues, compared to $4.8 million and 9.3% in the same period a year ago. Please note that all of the adjustments from GAAP to non-GAAP I discussed today are reconciled in our earnings press release issued this afternoon. Despite facing unexpected challenges, we maintained our strong financial position, ending the quarter with $17.8 million in cash and no debt. We also continued to maintain $5 million of availability under our revolving line of credit. We used $1.7 million in cash during the third quarter to repurchase approximately 326,000 common shares under our share repurchase authorization. As of March 31, 2022, there remains $28.1 million available under the authorization. Capital expenditures totaled $0.4 million in the third quarter. We anticipate total capital expenditures for fiscal 2022 to be approximately $2 million. Revenues for fiscal 2022 are now expected to be in the range of $204 million-$207 million. Adjusted non-GAAP EBITDA is expected to be in the range of approximately $15 million, and adjusted non-GAAP earnings are expected to be in the range of $0.52-$0.56 per share. With that, I'll turn the call back to Steve Fife. As we close, we note the challenges of our current environment, but recognize the groundwork we are laying for the future. We are focused on our unique portfolio of high quality, innovative products, supported by a large global base of distributors, along with the right management team focused on the opportunities ahead. Additionally, we continue to focus on maintaining a strong financial position and increasing value for our shareholders. With that, let me turn the call back over to the operator for questions. Operator? At this time, we will be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. Our first question comes from Douglas Lane with Lane Research. Please proceed with your question. Yes. Hi, good afternoon, everybody. Carl, can we start with the gross margins here? They're obviously very healthy, but they are the lowest they've been in recent quarters. I'm wondering, A, are you looking or have you done any pricing initiatives, all your products just in general? Then, B, can you talk a little bit more about the inventory obsolescence, specifically what was written off there? Yeah, sure, Doug, I'd be happy to address a couple of those. Regarding the inventory obsolescence, yeah, it was primarily related to one of our product lines, just our personal care line. That was a product line that we had entered into probably over the last year or so, and the demand hasn't been to what we had originally planned. That was some additional exposure recorded in the quarter associated with that line. We're hoping that that's it for that particular line, but we'll continue to watch that as we move forward. Regarding your other questions on cost of goods sold, we are continuing to see pressures similar to a lot of other companies in the current environment. In particular, we're seeing pressure on, especially on the shipping and the fulfillment side of the business. To counter that, we are evaluating other alternatives to potentially increase prices or to reevaluate other areas that we can help offset that. There are discussions underway, and we're currently evaluating options to address those issues. Okay, great. Thanks. That's helpful. Just to get a feel for the events, how they're shaping up, can you remind me how many people typically go to the Elite Academy? How big will the Activate 2022 event be? What are you expecting for the global convention in the fall? Yeah, Doug, this is Steve. At Elite Academy, all of these are gonna be hybrid events. We had right around 2,000 people at our Elite Academy in February in Orlando. The Activate 2022 event in June, I think it's gonna be less than that, probably in the 1,500-1,800 range. Part of that is driven by the venue that we're utilizing, just the timing of when we could pull that off. Slightly smaller in person, but we expect a very large online presence for that, in part because we are announcing a new product that I think there's going to be a lot of excitement around. The people that can't or aren't able to travel to Salt Lake in June, I believe they're going to be participating online. Then the global event where it's actually going to be in Phoenix this year, a kind of slight departure from our. Normally, we have it in Salt Lake City. You know, I think it's too early for us to tell just, especially from the international participation, how many people will be traveling to that in person. In the past, we've had 5,000-6,000 people, you know, pre-COVID. I'd be surprised if we were at that same level, but I think it's too early to predict the participation now. We haven't even opened it up for enrollments yet or registration yet. We are, you know, for the foreseeable future, we do anticipate doing hybrid approaches to all of these major meetings. Okay. No, I understand. That makes sense. Can we talk a little bit about distributor trends? I mean, you held sequentially in the international at a pretty good elevated level, but the Americas, it was flat sequentially and is down from where it was a couple of years ago. What can we look for as far as getting distributor growth back in the Americas? Is this Activate 2022 specifically for that purpose? Can we look to see sequential improvement in fiscal 2023? Or maybe just help me understand what we can do to get the distributor growth back in the Americas. Yeah. It's a great question and you know, one that we recognize. You know, at the beginning of this fiscal year for us, we really established two primary goals, and both of which you know, are supportive of increasing our active member base. That first goal was on distributor enrollments, you know, increasing the number of distributor enrollments. The second was on increasing the number of second orders placed. That obviously is tied to retention, but with a focus specifically on second orders. You know, as stated in our press release, year-over-year our distributors in the U.S. or in the Americas is down. What's encouraging to me is that it is flat from last quarter. You know, I want to believe, we believe that we've kind of bottomed on that front and we're turning the corner. We've seen significant improvement in that second goal that I mentioned, you know, the second orders, and that's true both for our distributors as well as our customers. It's really kind of an enrollment challenge that we've had. With Q3, our distributor enrollments turned to positive both over prior quarter and prior year. We're cautiously optimistic, as we say, around the fact that we've now bottomed. The whole, you know, our MVP incentive. It is really geared to distributors to bring in and enroll three distributors and then encourage them to enroll three distributors. It's kind of a 3 by 3 by 3. That's a, you know, it's an incentive that we have right now, but it is not a short-term, you know, let's grab some revenue for the quarter. It is a longer-term build around kind of the right principles and behaviors that we want our distributors to be focusing on. I mentioned, you know, just in the one month that we've had, you know, we had a 37% growth in the achievement of a goal associated with that. Again, cautiously optimistic, but those behaviors that we're now reinforcing around distributor enrollment and retention are helping to turn this tide in terms of both the distributor and then ultimately, you know, the customers will come, we know that. Okay, that's helpful. Thank you. All right, thanks, Doug. Our next question comes from Anthony Chiarenza with Key Equity Investors. Please proceed with your question. Thank you very much. Good afternoon. My question is, I'm a new shareholder, and obviously the fundamental issue here is the effectiveness of the product and the scientific data that you're able to demonstrate that the product works and is helping customers. Obviously, there's one part that's the customer reaction, and then there's another part that's, I don't know if it's a clinical analysis or clinical data, but can you take us through what the scientific support is for the product? I'm assuming it's the Nrf2 right now that's the main focus. Yeah. Thanks, Anthony, and appreciate your call. You're right. You know, our flagship product is Protandim Nrf2 Synergizer. It's the product that really the company was founded on. If you were to go to PubMed.org and look at the research around Protandim and oxidative stress. There are over 30 clinical studies and peer review studies that associate Protandim with oxidative stress. It's probably, you know, the best scientific resources out there for you to look at. It's what our distributors. You know, we have a very highly educated distributor force with a lot of people from the medical profession, and that's what they rely on as they talk to potential distributors and customers around the science behind that. Much of the technology that is built into Protandim also exists in other products that we provide, including our skin care line. Many of the same ingredients exist in that. I'd encourage you to look at PubMed.org and type in a few keywords to help you understand that a little bit further. Okay. Now is this an ongoing process now at this point? Is that you continue to do studies, or do you continue to do customer satisfaction surveys or? Because obviously, to the point that you can demonstrate, the more you can demonstrate that it's successful and people are happy, that obviously is gonna feed the distributors and everything else in the whole system. That's right. We do especially when we introduce new products. You know, I'm sure you picked up. I didn't do a word count on the number of times we used the word activate Right. In our prepared remarks. That is a differentiator for LifeVantage and our products, is that it activates what our bodies naturally do. There is a synergistic benefit, when you consume our Protandim Nrf2 product with NRF1 and with NAD, so other products. We do have studies around the incremental benefit that comes by consumption of, you know, not just Nrf2, but it in tandem or in parallel with other products that we have. Okay. That'll continue to be the case as we introduce new products, you know. There will be continued kind of correlation between how a new product activates a pathway in the body, but also the benefits of us utilizing it in tandem with Protandim Nrf2. Okay. Now, I was gonna ask another question. Oh, the competition. Who do you consider your greatest competition in this product in the field right now? Well, you know, we're in a unique situation where there's not another product out in the world that I'm aware of that has the patented technology and the peer review studies that Nrf2 has. Okay. Not in terms of antioxidants or people selling vitamins and calling them antioxidants or things that reduce free radicals and so forth. Wouldn't that be such a competition for you? It is, but there's a big difference between activation and nutrigenomics, you know, enhancing what the body naturally does versus supplementing what the body does. Okay. All right. Thank you very much and best of luck. Thank you. Thank you. Our next question is from Ron Zola with QJR Partnership. Please proceed with your question. Hello. Hey, Steve. Hey, Carl. I'm also a shareholder. I have a question relating to the dividend policy. My understanding that that's now going to be a quarterly dividend. I kind of loved your capital allocation of buying back shares as a shareholder because I believe that the intrinsic value of your shares when you look at free cash flow and free cash flow potential is much lower than the current share price. As a shareholder, I like the fact that you're using free cash flow to buy back shares because I think that does a better job of maximizing shareholder value. Secondly, I'm concerned. The reason I love this company is because of the potential for growth. If you can increase the productivity of the productive distributor pool and identify those new distributors where you guys need to put the energy on to get them into that productive pool, the revenues will grow. If you can protect your margins, good things will happen for this company, and that will drive my confidence as a shareholder. My concern about the dividend is that it's signaling it could be perceived as a negative signal for growth, that the company's now, you know, going into a new phase, and the new phase isn't all about growth. It's about dividend payments. Sometimes what'll happen is shareholders will turn over, and those seeking dividends will come. You're locking yourself into a quarterly dividend. I know your thought process is you're giving the shareholders the confidence that the dividends will be there. I just kinda wonder whether your existing strategy of buying back shares and focusing in on the growth is the best strategy for shareholder maximization. I'd like you guys to talk to me about that. Yeah. Ron, this is Steve, and I appreciate your question and wondering if you might want a job at LifeVantage, thinking through the revenue growth strategy because, you know, we've spent a lot of time. I couldn't agree more with you that. Well, first and foremost, revenue growth is what's ultimately gonna drive the best long-term shareholder value. Too, you know, the initiatives that we have in place are focused, absolutely, 100% on those areas of growth. Your comment around focusing, and these are maybe my words, not yours, but you know, on those distributors earlier in their journey to incentivize, motivate, inspire them to understand the opportunities that they have to participate, both from a product standpoint and a business opportunity, is very high on our list of priorities. Accelerating and bringing people in earlier to understand, you know, just the magnitude of this opportunity and getting them excited about that is where a lot of our focus and attention is. I think you and I are very much aligned on that. I think there's also very definitive reasons why we introduced a dividend at this time. I'm gonna let Carl answer those, and then follow up if there's any additional comments I have. Yeah. Thanks, Steve. I can add a couple comments regarding the dividend. I mean, it was a careful consideration that we went through. Really from our perspective as we evaluated it really is finding that right balance between the share repurchase program that historically we followed, as well as looking for other alternatives to maximize shareholder value. I don't know that it shouldn't be interpreted as we're abandoning the share repurchase program. It's really we're finding that balance between the two. As we've evaluated other peers and gone through our analysis that we felt that balance was appropriate for where we are in our current stage of our company. Yeah. We are continuing. You know, we still have, you know, tens of millions of dollars. Yeah, $28 million. $28 million available under our share repurchase plan. We're not signaling that we're gonna need to stop repurchasing shares, but we thought having a balanced approach to both repurchasing and a dividend. We clearly are not signaling with this, that with the introduction of a dividend that we're resigning to a value stock, because we know we know the opportunity that we have here to drive meaningful shareholder value through our revenue growth. Thanks for your question, though. Ladies and gentlemen, we have reached the end of the question and answer session, and I would like to turn the call back over to Mr. Fife for closing remarks. Thanks, Maria, and thank you everyone for joining us today. In closing, I just wanna take an opportunity to thank all of our employees for their hard work and dedication, as well as our outstanding team of distributors and loyal customers. We remain confident in our business model and are focused on delivering the LifeVantage products our customers depend on. We hope you stay safe and are healthy and look forward to updating you on our next call. Have a great day. Thanks. This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.